DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries ...

Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on Dexcom (DXCM – Research Report) and keeping the price target at $75.00. Patrick Wood has given his Hold rating due to a ...

Oct 24 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient demand for its continuous ...

Shares of Dexcom (NASDAQ:DXCM) fell 16% in post-market trading Thursday after the company released its Q3 earnings report which showed only modest topline growth over last year’s quarter.